Cargando…

Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease

To induce remission in luminal paediatric Crohn’s disease (CD), the ESPGHAN/ECCO guideline recommends treatment with exclusive enteral nutrition (EEN) or oral corticosteroids. In newly diagnosed moderate-to-severe paediatric CD patients, we determined the proportion of patients in which EEN or corti...

Descripción completa

Detalles Bibliográficos
Autores principales: Jongsma, Maria M. E., Vuijk, Stephanie A., Cozijnsen, Martinus A., van Pieterson, Merel, Norbruis, Obbe F., Groeneweg, Michael, Wolters, Victorien M., van Wering, Herbert M., Hojsak, Iva, Kolho, Kaija-Leena, van Wijk, Michiel P., Teklenburg-Roord, Sarah T. A., de Meij, Tim G. J., Escher, Johanna C., de Ridder, Lissy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352605/
https://www.ncbi.nlm.nih.gov/pubmed/35672586
http://dx.doi.org/10.1007/s00431-022-04496-7
_version_ 1784762684556705792
author Jongsma, Maria M. E.
Vuijk, Stephanie A.
Cozijnsen, Martinus A.
van Pieterson, Merel
Norbruis, Obbe F.
Groeneweg, Michael
Wolters, Victorien M.
van Wering, Herbert M.
Hojsak, Iva
Kolho, Kaija-Leena
van Wijk, Michiel P.
Teklenburg-Roord, Sarah T. A.
de Meij, Tim G. J.
Escher, Johanna C.
de Ridder, Lissy
author_facet Jongsma, Maria M. E.
Vuijk, Stephanie A.
Cozijnsen, Martinus A.
van Pieterson, Merel
Norbruis, Obbe F.
Groeneweg, Michael
Wolters, Victorien M.
van Wering, Herbert M.
Hojsak, Iva
Kolho, Kaija-Leena
van Wijk, Michiel P.
Teklenburg-Roord, Sarah T. A.
de Meij, Tim G. J.
Escher, Johanna C.
de Ridder, Lissy
author_sort Jongsma, Maria M. E.
collection PubMed
description To induce remission in luminal paediatric Crohn’s disease (CD), the ESPGHAN/ECCO guideline recommends treatment with exclusive enteral nutrition (EEN) or oral corticosteroids. In newly diagnosed moderate-to-severe paediatric CD patients, we determined the proportion of patients in which EEN or corticosteroids induced remission and maintained remission on azathioprine monotherapy. We included patients from the “TISKids” study assigned to the conventional treatment arm. Patients were aged 3–17 years and had new-onset, untreated luminal CD with weighted paediatric CD activity index (wPCDAI) > 40. Induction treatment consisted of EEN or oral corticosteroids; all received azathioprine maintenance treatment from start of treatment. The primary outcome of this study was endoscopic remission defined as a SES-CD score < 3 without treatment escalation at week 10. Secondary outcomes included proportion of patients without treatment escalation at week 52. In total, 27/47 patients received EEN and 20/47 corticosteroids. At baseline, patient demographics and several inflammation parameters were similar between the two treatment groups. At 10 weeks, clinical remission rates were 7/23 (30%) for EEN and 7/19 (37%) for corticosteroids (p = 0.661). Twenty-nine of 47 consented to endoscopy at 10 weeks, showing endoscopic remission rates without treatment escalation in 2/16 (13%) of EEN-treated patients and in 1/13 (8%) of corticosteroid-treated patients (p = 1.00). At week 52, 23/27 (85%) EEN-treated patients received treatment escalation (median 14 weeks) and 13/20 (65%) corticosteroid-treated patients (median 27 weeks), p = 0.070. Conclusion: In children with moderate-to-severe newly diagnosed CD, induction treatment with EEN or CS regularly is insufficient to achieve endoscopic remission without treatment escalation at week 10. Trial registration number: NCT02517684 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00431-022-04496-7.
format Online
Article
Text
id pubmed-9352605
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93526052022-08-06 Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease Jongsma, Maria M. E. Vuijk, Stephanie A. Cozijnsen, Martinus A. van Pieterson, Merel Norbruis, Obbe F. Groeneweg, Michael Wolters, Victorien M. van Wering, Herbert M. Hojsak, Iva Kolho, Kaija-Leena van Wijk, Michiel P. Teklenburg-Roord, Sarah T. A. de Meij, Tim G. J. Escher, Johanna C. de Ridder, Lissy Eur J Pediatr Original Article To induce remission in luminal paediatric Crohn’s disease (CD), the ESPGHAN/ECCO guideline recommends treatment with exclusive enteral nutrition (EEN) or oral corticosteroids. In newly diagnosed moderate-to-severe paediatric CD patients, we determined the proportion of patients in which EEN or corticosteroids induced remission and maintained remission on azathioprine monotherapy. We included patients from the “TISKids” study assigned to the conventional treatment arm. Patients were aged 3–17 years and had new-onset, untreated luminal CD with weighted paediatric CD activity index (wPCDAI) > 40. Induction treatment consisted of EEN or oral corticosteroids; all received azathioprine maintenance treatment from start of treatment. The primary outcome of this study was endoscopic remission defined as a SES-CD score < 3 without treatment escalation at week 10. Secondary outcomes included proportion of patients without treatment escalation at week 52. In total, 27/47 patients received EEN and 20/47 corticosteroids. At baseline, patient demographics and several inflammation parameters were similar between the two treatment groups. At 10 weeks, clinical remission rates were 7/23 (30%) for EEN and 7/19 (37%) for corticosteroids (p = 0.661). Twenty-nine of 47 consented to endoscopy at 10 weeks, showing endoscopic remission rates without treatment escalation in 2/16 (13%) of EEN-treated patients and in 1/13 (8%) of corticosteroid-treated patients (p = 1.00). At week 52, 23/27 (85%) EEN-treated patients received treatment escalation (median 14 weeks) and 13/20 (65%) corticosteroid-treated patients (median 27 weeks), p = 0.070. Conclusion: In children with moderate-to-severe newly diagnosed CD, induction treatment with EEN or CS regularly is insufficient to achieve endoscopic remission without treatment escalation at week 10. Trial registration number: NCT02517684 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00431-022-04496-7. Springer Berlin Heidelberg 2022-06-08 2022 /pmc/articles/PMC9352605/ /pubmed/35672586 http://dx.doi.org/10.1007/s00431-022-04496-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Jongsma, Maria M. E.
Vuijk, Stephanie A.
Cozijnsen, Martinus A.
van Pieterson, Merel
Norbruis, Obbe F.
Groeneweg, Michael
Wolters, Victorien M.
van Wering, Herbert M.
Hojsak, Iva
Kolho, Kaija-Leena
van Wijk, Michiel P.
Teklenburg-Roord, Sarah T. A.
de Meij, Tim G. J.
Escher, Johanna C.
de Ridder, Lissy
Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease
title Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease
title_full Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease
title_fullStr Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease
title_full_unstemmed Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease
title_short Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease
title_sort evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric crohn’s disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352605/
https://www.ncbi.nlm.nih.gov/pubmed/35672586
http://dx.doi.org/10.1007/s00431-022-04496-7
work_keys_str_mv AT jongsmamariame evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT vuijkstephaniea evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT cozijnsenmartinusa evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT vanpietersonmerel evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT norbruisobbef evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT groenewegmichael evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT woltersvictorienm evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT vanweringherbertm evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT hojsakiva evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT kolhokaijaleena evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT vanwijkmichielp evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT teklenburgroordsarahta evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT demeijtimgj evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT escherjohannac evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease
AT deridderlissy evaluationofexclusiveenteralnutritionandcorticosteroidinductiontreatmentinnewonsetmoderatetosevereluminalpaediatriccrohnsdisease